Review
Version 1
Preserved in Portico This version is not peer-reviewed
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Version 1
: Received: 29 September 2020 / Approved: 29 September 2020 / Online: 29 September 2020 (15:09:47 CEST)
A peer-reviewed article of this Preprint also exists.
Harris, L.J.; Patel, K.; Martin, M. Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Int. J. Mol. Sci. 2020, 21, 8553. Harris, L.J.; Patel, K.; Martin, M. Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Int. J. Mol. Sci. 2020, 21, 8553.
Abstract
The most common type of non-Hodgkin lymphoma in adults is diffuse large B-cell (DLBCL). There is a historical unmet need for more effective therapies in the 2nd and 3rd line setting. Emerging immunochemotherapies have shown activity in small studies of heavily pre-treated patients with prolonged remissions achieved in some patients. Anti-CD19 CAR (chimeric antigen receptor) T cells are potentially curative in the 3rd line and beyond setting and are under investigation in earlier lines of therapy.1 Antibody-drug conjugates (ADC’s) such as polatuzumab vedotin targeting the pan-B-cell marker CD79b has proven effectiveness in multiply-relapsed DLBCL patients. Tafasitamab (MOR208) is an anti-CD19 monoclonal antibody producing prolonged remissions when combined with Lenalidomide in patients who were not candidates for salvage chemotherapy or autologous stem cell transplant. Selinexor, an oral, small-molecule selective inhibitor of XPO1-mediated nuclear export (SINE), demonstrated prolonged activity against heavily-pretreated DLBCL without cumulative toxicity and is being investigated as part of an oral, chemotherapy-free regimen for relapsed aggressive lymphoma. This article reviews current strategies and novel therapies for relapsed/refractory DLBCL.
Keywords
Relapsed or Refractory Diffuse Large B Cell Lymphoma, DLBLC, immunotherapy, chemotherapy-free regimen
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment